Corbus Pharmaceuticals Holdings (CRBP) Net Income towards Common Stockholders (2013 - 2025)

Corbus Pharmaceuticals Holdings' Net Income towards Common Stockholders history runs 13 years deep, the most recent figure standing at -$24.4 million for Q3 2025.

• On a quarterly basis, Net Income towards Common Stockholders fell 34.86% year-over-year to -$24.4 million in Q3 2025; TTM through Dec 2025 was -$24.5 million, a 37.64% increase from a year earlier, with the FY2024 full-year figure at $3.5 million, up 102.49% from the prior year.
• Net Income towards Common Stockholders slipped to -$24.4 million in Q3 2025 per CRBP's latest filing, from $1.3 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $1.9 million in Q4 2024 and bottomed at -$54.0 million in Q2 2021.
• The 5-year median for Net Income towards Common Stockholders is -$18.2 million (2023), against an average of -$20.1 million.
• Across the five-year window, Net Income towards Common Stockholders soared 117.27% in 2024 and slumped 819.05% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$10.4 million in 2021, then decreased by 1.34% to -$10.6 million in 2022, then retreated by 1.43% to -$10.7 million in 2023, then surged by 117.27% to $1.9 million in 2024, then plunged by 1418.41% to -$24.4 million in 2025.
• Per Business Quant, the three latest CRBP Net Income towards Common Stockholders figures stand at -$24.4 million (Q3 2025), $1.3 million (Q2 2025), and -$1.4 million (Q1 2025).